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OBJECTIVES: FIBROSCAN® is an ultrasound elastography
based non-invasive liver ﬁbrosis assessment device. This new
technology is aimed to replace or diminish the number of inva-
sive liver biopsy performed. The purpose of this study was to
compare, in terms of life expectancy and lifetime costs, a 5-year
periodic liver biopsy follow-up of HCV infected patients to an
annual liver ﬁbrosis assessment using FIBROSCAN® which
is assumed to allow an earlier antiviral treatment initiation.
METHODS: A discrete event simulation was developed. The
model simulates the lifetime follow-up of a cohort of 10,000
HCV newly infected individuals. The Health Insurance perspec-
tive was used and costs were discounted using a 3% rate. Direct
medical costs were derived from French ofﬁcial sources. The
model was populated with published clinical trial data and other
published studies. RESULTS: Death rate from hepatic mortality
was reduced by 0.68% (68 deaths prevented over the whole
cohort) with FIBROSCAN®. The survival gain was 0.07 year/
patient that is 10.3 years for the 68 avoided deaths. The average
cost of the disease was of €11,545/patient with FIBROSCAN®
compared with €12,510/patient in the case of biopsy. When
biopsy was performed every 3 years, there were no survival gain
but savings of 3, 722€/patient. At every 10 years, FIBROSCAN®
follow-up remained a cost-effective strategy allowing a 3.53%
reduction of hepatic death (353 deaths prevented over the whole
cohort) and a survival gain of 0.39 year/patient (p < 0,001). In
this latter case, the cost per life year gained was 810€ which is
largely below the ratios commonly cited in such analysis. CON-
CLUSION: FIBROSCAN® is a dominant strategy. Compared to
a periodic hepatic ﬁbrosis follow-up with liver biopsy, FIBROS-
CAN® helps reducing hepatic mortality, increasing patients’ life
expectancy and diminishing the costs associated with managing
patients chronically infected with HCV.
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OBJECTIVES: Despite good vaccination coverage rates and
good a-cellular pertussis vaccine efﬁcacy the incidence is still
relatively high in The Netherlands. Pertussis is most severe in
infants too young for already having completed the primary
immunization schedule. For protection of young infants (below
one year of age) further strategies should be considered. It is
known that household members are an important source of
transmission for these infants. The objective of this study was to
analyze cost-effectiveness of speciﬁc vaccination strategies in The
Netherlands explicitly targeting pertussis in these young infants.
METHODS: Data were extracted from national registries on
incidence, hospitalizations and neonatal intensive care. Addition-
ally, literature and expert consultations were used to complete
information on morbidity and accompanying direct costs for
pertussis in infants. A static decision analysic model was
constructed for estimating health outcomes and costs potentially
associated with different vaccination strategies. The strategies
investigated were cocooning (father and mother), pre- and post-
pregnancy maternal immunization, all to protect the infant for
transmission of pertussis in the household setting. RESULTS:
Relatively, the potential most effective strategy would to be
cocooning. However this would also be the most expensive.
Compared to do-nothing, incremental cost-effectiveness of the
three strategies varied from €15,000 to just over €100,000 per
hospitalization averted in the base case. Results appeared to be
robust in sensitivity analysis. Under plausible assumptions,
pre-pregnancy maternal immunization could well be the most
cost-effective strategy. We note that the overall impact on total
numbers of infections among young infants obviously crucially
depends on the vaccination coverage achieved. CONCLUSION:
Cost-effectiveness analysis as presented here is crucial in the
Dutch decision making concerning additional pertussis vaccina-
tion strategies to protect young infants against severe disease.
Further research is needed to fully assess the effectiveness of these
strategies, inclusive the application of dynamical models for the
spread of pertussis.
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OBJECTIVES: Hepatitis C is a disease affecting approximately
180 million people worldwide (WHO 2006) and is one of the
main causes of chronic hepatic disease. HCV infection progresses
to chronic form in 80% of infected individuals. Approximately
20% progress to cirrhosis over 20 years and, consequently, a
high risk of developing hepatocellular carcinoma population.
Our objective is to assess the incremental cost-effectiveness
ratio (ICER) of peginterferon-alfa-2a (40 KD) plus ribavirin
(PEG + RBV) versus interferon-alfa-2b plus ribavirin (IFN +
RBV) in the treatment of patients with chronic hepatitis
C, genotypes 2 and 3 in the Brazilian payer perspective.
METHODS: A Markov model was built to estimate the clinical
and economic impact related to the incorporation of
peginterferon-alfa-2a (40 KD). Clinical stages were based on
liver histology, forms of cirrhotic decompensation, liver cancer
and liver transplantation. A Delphi panel was performed for
evaluating the direct medical resources related to each clinical
stage in chronic hepatitis C, as well as costs from treatment with
peginterferon-alfa-2a (40 KD), interferon alfa-2b and ribavirin.
Effectiveness of treatment with peginterferon-alfa-2a (40 KD)
was obtained from a multicenter, controlled, randomized trial
involving 1,121 naive patients with chronic hepatitis C (Fried,
M. W. et al, 2002). We have assumed a discount rate of 3.5% for
costs and outcomes according to NICE and a lifetime horizon. A
sensitivity analysis was conducted using second-order Monte
Carlo simulation. Tested parameters were costs per stage, treat-
ment costs, discount rate, response rate to treatment and early
patient distribution. RESULTS: The ICER of PEG + RBV versus
IFN + RBV was approximately R$18,627 per life year gained
(LYG). The 95% conﬁdence interval for the ICER ranged from
R$9,571 to R$29,090. CONCLUSION: The study suggests
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